Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.

Borena W, Grünberger M, Widschwendter A, Kraxner KH, Marth E, Mayr P, Meier J, Ruth N, Guerrero AT, Marth C, Holm-von Laer D.

BMC Public Health. 2016 Aug 26;16:889. doi: 10.1186/s12889-016-3581-0.

2.

The impact of sexual behavior on oral HPV infections in young unvaccinated adults.

Dalla Torre D, Burtscher D, Sölder E, Widschwendter A, Rasse M, Puelacher W.

Clin Oral Investig. 2016 Sep;20(7):1551-7. doi: 10.1007/s00784-015-1633-y. Epub 2015 Nov 3.

PMID:
26526324
3.

Comparison of the prevalence of human papilloma virus infection in histopathologically confirmed premalignant oral lesions and healthy oral mucosa by brush smear detection.

Dalla Torre D, Burtscher D, Edlinger M, Sölder E, Widschwendter A, Rasse M, Puelacher W.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Mar;119(3):333-9. doi: 10.1016/j.oooo.2014.11.013. Epub 2014 Dec 5.

PMID:
25600980
4.

Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.

Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, Bonn GK, Fiegl H.

Int J Mol Sci. 2012;13(7):8353-63. doi: 10.3390/ijms13078353. Epub 2012 Jul 5.

5.

HE4 is an independent prognostic marker in endometrial cancer patients.

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A.

Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.

PMID:
22525819
6.

Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy.

Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward DG, Vogel W, Zoller H.

Blood Cells Mol Dis. 2012 Apr 15;48(4):233-7. doi: 10.1016/j.bcmd.2012.02.001. Epub 2012 Feb 25.

PMID:
22365732
7.

Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Ehehalt D, Lener B, Pircher H, Dreier K, Pfister H, Kaufmann AM, Frangini S, Ressler S, Müller-Holzner E, Schmitt M, Höfler D, Rostek U, Kaiser A, Widschwendter A, Zwerschke W, Jansen-Dürr P.

J Clin Microbiol. 2012 Feb;50(2):246-57. doi: 10.1128/JCM.01108-11. Epub 2011 Nov 30.

8.

Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ.

Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Müller-Holzner E, Rostek U, Kaiser A, Fiedler M, Ressler S, Lechner S, Widschwendter A, Even J, Capesius C, Jansen-Dürr P, Zwerschke W.

Virology. 2011 Jan 5;409(1):54-68. doi: 10.1016/j.virol.2010.09.024. Epub 2010 Oct 23.

9.

Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen.

Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, Volgger B, Widschwendter A, Staudach A.

Am J Obstet Gynecol. 2010 Oct;203(4):321.e1-6. doi: 10.1016/j.ajog.2010.05.033. Epub 2010 Jul 14.

PMID:
20633870
10.

[Anal HPV infections].

Aigner F, Conrad F, Widschwendter A, Zangerle R, Zelger B, Haidenberger A, Roka S, Heim K, Höpfl R, Klimpfinger M, Rigler YM, Bonatti H, Pfeifer J, Maier A, Kirnbauer R, Salat A.

Wien Klin Wochenschr. 2008;120(19-20):631-41. doi: 10.1007/s00508-008-1059-5. German. No abstract available.

PMID:
19083168
11.

High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.

Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR, Widschwendter A, Even J, Jansen-Dürr P, Capesius C, Zwerschke W.

Clin Cancer Res. 2007 Dec 1;13(23):7067-72.

12.

Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies.

Fiedler M, Ressler S, Campo-Fernández B, Laich A, Jansen L, Widschwendter A, Viertler HP, Bacher N, Morandell D, Müller-Holzner E, Dürst M, Jansen-Dürr P, Zwerschke W.

J Gen Virol. 2005 Dec;86(Pt 12):3235-41.

PMID:
16298968
13.

Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions.

Heim K, Widschwendter A, Szedenik H, Geier A, Christensen ND, Bergant A, Concin N, Höpfl R.

Am J Obstet Gynecol. 2005 Apr;192(4):1073-83.

PMID:
15846183
14.

Comparison of different scoring methods for assessing the nutritional status of hospitalised patients.

Galvan O, Joannidis M, Widschwendter A, Bonatti H, Sprinzl GM, Rehak P, Balogh D, Hackl JM.

Wien Klin Wochenschr. 2004 Sep 30;116(17-18):596-602.

PMID:
15515876
15.

Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.

Müller HM, Millinger S, Fiegl H, Goebel G, Ivarsson L, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M.

Clin Chem. 2004 Nov;50(11):2171-3. No abstract available.

16.

Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history.

Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C.

J Clin Virol. 2004 Dec;31(4):292-7.

PMID:
15494272
17.

Prognostic DNA methylation marker in serum of cancer patients.

Müller HM, Fiegl H, Widschwendter A, Widschwendter M.

Ann N Y Acad Sci. 2004 Jun;1022:44-9.

PMID:
15251938
18.

DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients.

Müller HM, Ivarsson L, Schröcksnadel H, Fiegl H, Widschwendter A, Goebel G, Kilga-Nogler S, Philadelphy H, Gütter W, Marth C, Widschwendter M.

Clin Chem. 2004 Jun;50(6):1065-8. No abstract available.

19.

Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors.

Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, Müller HM, Wiedemair A, Jerabek S, Müller-Holzner E, Goebel G, Marth C, Widschwendter M.

Clin Cancer Res. 2004 May 15;10(10):3396-400.

20.

Methylated DNA collected by tampons--a new tool to detect endometrial cancer.

Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Müller HM, Mueller-Holzner E, Marth C, Widschwendter M.

Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):882-8.

21.

A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer.

Müller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A, Müller-Holzner E, Marth C, Widschwendter M.

Cancer Lett. 2004 Jun 25;209(2):231-6.

PMID:
15159026
22.

High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies.

Fiedler M, Müller-Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen-Dürr P, Zwerschke W.

FASEB J. 2004 Jul;18(10):1120-2. Epub 2004 May 20.

PMID:
15155561
23.

Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.

Widschwendter A, Müller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M.

Gynecol Oncol. 2004 May;93(2):407-16.

PMID:
15099954
24.

Cyclin E dysregulation and chromosomal instability in endometrial cancer.

Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Müller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M.

Oncogene. 2004 May 20;23(23):4187-92.

PMID:
15048079
25.

DNA methylation in serum and tumors of cervical cancer patients.

Widschwendter A, Müller HM, Fiegl H, Ivarsson L, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M.

Clin Cancer Res. 2004 Jan 15;10(2):565-71.

26.

CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.

Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M.

Int J Cancer. 2004 Mar 20;109(2):163-6.

27.

Human papillomavirus DNA in sera of cervical cancer patients as tumor marker.

Widschwendter A, Blassnig A, Wiedemair A, Müller-Holzner E, Müller HM, Marth C.

Cancer Lett. 2003 Dec 30;202(2):231-9.

PMID:
14643453
28.

DNA methylation in serum of breast cancer patients: an independent prognostic marker.

Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M.

Cancer Res. 2003 Nov 15;63(22):7641-5.

29.

MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status.

Müller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Müller-Holzner E, Marth C, Widschwendter M.

Br J Cancer. 2003 Nov 17;89(10):1934-9.

30.

High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study.

Höpfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R.

BMC Infect Dis. 2003 Apr 30;3:6.

31.

Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.

Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W.

Clin Cancer Res. 2002 Oct;8(10):3065-74.

32.

HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.

Sehr P, Müller M, Höpfl R, Widschwendter A, Pawlita M.

J Virol Methods. 2002 Oct;106(1):61-70.

PMID:
12367730
33.

Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer.

Heim K, Widschwendter A, Pirschner G, Wieland U, Awerkiew S, Christensen ND, Bergant A, Marth C, Höpfl R.

Am J Obstet Gynecol. 2002 Apr;186(4):705-11.

PMID:
11967495
34.

Prenatal diagnosis of de novo mosaic deletion 13q associated with multiple abnormalities.

Widschwendter A, Riha K, Duba HC, Kreczy A, Marth C, Schwärzler P.

Ultrasound Obstet Gynecol. 2002 Apr;19(4):396-9.

35.

[Human papillomaviruses and their role in carcinogenesis].

Höpfl R, Guger M, Widschwendter A.

Hautarzt. 2001 Sep;52(9):834-45; quiz 846-8. German. No abstract available.

PMID:
11572080
36.

Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.

Höpfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Müller-Holzner E, Pawlita M, Pfister H, Fritsch P.

Lancet. 2000 Dec 9;356(9246):1985-6.

PMID:
11130532
37.

Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer.

Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C.

J Natl Cancer Inst. 2000 May 17;92(10):826-32.

PMID:
10814678
38.

Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro.

Widschwendter M, Widschwendter A, Welte T, Daxenbichler G, Zeimet AG, Bergant A, Berger J, Peyrat JP, Michel S, Doppler W, Marth C.

Br J Cancer. 1999 Jan;79(2):204-10.

39.

Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer.

Widschwendter M, Berger J, Daxenbichler G, Müller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG.

Cancer Res. 1997 Oct 1;57(19):4158-61.

40.

Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines.

Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zeimet AG, Mörtl MG, Widschwendter A, Marth C.

Int J Cancer. 1997 May 2;71(3):497-504.

Supplemental Content

Loading ...
Support Center